RxDoctor Payments Data

Kate Tripp, PA

Physician Assistant · West Des Moines, IANPI 1073949236

Payments from drug & device makers

$1,094in general payments, 2019–2025

Across 43 payments — averaging $25.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$168
  • Endo Pharmaceuticals Inc.$130
  • Axonics, Inc.$125
  • 180 Medical, Inc.$117
  • Novo Nordisk$116
  • Teleflex LLC$86
  • plus $352 from 12 others

What the payments were for

  • Food & beverage$1,02994%
  • Education$656%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,094 in reported general payments places this provider in the 80th percentile of 1,140 physician assistant providers in Iowa.

See all physician assistant providers in Iowa

Medicare billing

Part B allowed, 2024
$154,972
Medicare patients
508
Services billed
8,205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron260$184,850
GemtesaVibegron216$151,031
Tamsulosin Hcl914$18,270
ElmironPentosan Polysulfate Sodium13$10,575
Methenamine Hippurate136$10,250
Estradiol94$7,269
Fesoterodine Fumarate ErFesoterodine Fumarate54$6,291
Finasteride535$6,127
Solifenacin Succinate112$4,997
Potassium Citrate ErPotassium Citrate37$4,018
Desmopressin Acetate37$2,644
Oxybutynin Chloride ErOxybutynin Chloride133$2,593
Trimethoprim49$2,409
Alfuzosin Hcl ErAlfuzosin Hcl130$2,172
Tolterodine Tartrate ErTolterodine Tartrate40$1,935

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$65$184,850260 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,140 physician assistant providers in Iowa.

Other physician assistant in West Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →